Oncotelic Therapeutics Inc. is advancing nanoparticle-based drug delivery strategies through its Deciparticle platform, positioning the company at the forefront of pharmaceutical innovation in cancer therapy. The company is preparing its first-in-human study of an intravenous Everolimus nanoformulation, codeveloped with subsidiary Sapu Nano, designed to overcome absorption and tumor-penetration limitations of conventional oral Everolimus treatments.
The contemporary pharmaceutical view holds that nanocarrier-enabled formulations may be as transformative for drug delivery as monoclonal antibodies were for biologics, according to industry analysis. Nanoparticle delivery offers significant advantages in bioavailability, precision targeting, and therapeutic performance of anticancer compounds. Oncotelic's approach through its joint venture entity represents a strategic advancement in how nanotechnology can enhance existing cancer therapies.
The company's Sapu-003 formulation delivers full bioavailability via intravenous nanoparticle delivery, addressing what the company identifies as key limitations of conventional oral Everolimus. This development comes as Oncotelic maintains its focus on oncology and immunotherapy products, with a mission to address high-unmet-need cancers and rare pediatric indications with innovative therapeutic candidates.
Beyond its internal programs, Oncotelic licenses and codevelops select drug candidates through joint ventures, including its 45% ownership of GMP Bio. The company benefits from the intellectual property portfolio of CEO Dr. Vuong Trieu, who has filed more than 150 patent applications and holds 39 issued U.S. patents. This foundation supports the company's strategic position in advancing novel drug delivery technologies.
The advancement of nanoparticle drug delivery systems represents a significant shift in cancer treatment approaches, potentially enabling more effective administration of existing therapeutics. As Oncotelic moves toward human trials with its intravenous Everolimus formulation, the pharmaceutical industry watches closely for developments that could reshape how anticancer compounds are delivered to patients. Additional information about the company is available through its newsroom at https://ibn.fm/OTLC.
